Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncotelic Therapeutics Inc (OP: OTLC )

0.0530 -0.0010 (-1.85%)
Streaming Delayed Price Updated: 2:04 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncotelic Therapeutics Inc

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets 
Via News Direct
Exposures Product Safety
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial 
Via News Direct
Topics Death
Exposures Death
Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments
--News Direct-- 
Via News Direct
Exposures COVID-19
Oncotelic Therapeutics’ (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
--News Direct-- 
Via News Direct
Exposures COVID-19
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging. 
Via Benzinga
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
--News Direct-- 
Via News Direct
Exposures COVID-19
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. 
Via Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
--News Direct-- 
Via News Direct
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones,... 
Via Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Charge
Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones,... 
Via Benzinga
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Announces Formation of Animal Health Division
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and... 
Via Talk Markets
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022 
Via News Direct
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY 
Via News Direct
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Legal
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.